XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment … Read more
Market Cap & Net Worth: XORTX Therapeutics Inc (XRTX)
XORTX Therapeutics Inc (NASDAQ:XRTX) has a market capitalization of $2.92 Million ($2.92 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #33441 globally and #10928 in its home market, demonstrating a -10.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XORTX Therapeutics Inc's stock price $0.42 by its total outstanding shares 6962218 (6.96 Million).
XORTX Therapeutics Inc Market Cap History: 2018 to 2026
XORTX Therapeutics Inc's market capitalization history from 2018 to 2026. Data shows growth from $71.01K to $2.92 Million (56.50% CAGR).
Index Memberships
XORTX Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2671 of 3165 |
Weight: XORTX Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
XORTX Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XORTX Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of XRTX by Market Capitalization
Companies near XORTX Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to XORTX Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
XORTX Therapeutics Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, XORTX Therapeutics Inc's market cap moved from $71.01K to $ 2.92 Million, with a yearly change of 56.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.92 Million | -25.37% |
| 2025 | $3.91 Million | -50.25% |
| 2024 | $7.86 Million | -51.10% |
| 2023 | $16.08 Million | -96.47% |
| 2022 | $455.66 Million | -60.59% |
| 2021 | $1.16 Billion | +1287109.30% |
| 2020 | $89.81K | -11.03% |
| 2019 | $100.95K | +42.16% |
| 2018 | $71.01K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of XORTX Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.92 Million USD |
| MoneyControl | $2.92 Million USD |
| MarketWatch | $2.92 Million USD |
| marketcap.company | $2.92 Million USD |
| Reuters | $2.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.